Mats Wahlström has served as Chairman of the board of directors of TriSalus since January 2017. Mats has also served as the Co-Chairman of HW Investment Partners, LLC since July 2016 and as Partner and Executive Chairman of KMG Capital Partners, LLC since April 2012, both investment funds focused on investments in the healthcare industry.
In addition, Mats has served as the Chairman of the board of directors of Triomed AB since October 2016, as the lead independent director of Coherus Biosciences, Inc., a public biotech company, since January 2012 and as Chairman of Caduceus Medical Holdings, Inc. since August 2010. Mats has served on the boards of directors of Alteco Medical AB since October 2012, Circuit Clinical Solutions, Inc. since July 2016 and PCI | HealthDev since August 2010. He served as a director of Health Grades, Inc. a Nasdaq-listed healthcare ratings company, from March 2009 through its sale to a private equity firm in October 2010, as a director of Getinge AB, a Swedish Stock Exchange-listed medical device company, from March 2012 to March 2017, and as a director of Zynex Inc. an over-the-counter medical device manufacturer, from October 2010 through January 2014. From January 2004 to December 2009, Mats served as co-CEO of Fresenius Medical Care North America and a member of the management board at Fresenius Medical Care AG & Co. KGaA. From November 2002 to December 2009, Mats served as President and Chief Executive Officer of Fresenius Medical Services. Prior to that, Mats held various positions at Gambro AB in Sweden from January 1983 to February 2000, including President of Gambro North America and Chief Executive Officer of Gambro Healthcare Inc. as well as Chief Financial Officer of the Gambro Group.
Mats has a B.S. degree in Economics and Business Administration from the University of Lund, Sweden.
What is Mats Wahlstrom's net worth?
The estimated net worth of Mats Wahlstrom is at least $619.73 thousand as of May 15th, 2026. Wahlstrom owns 147,555 shares of TriSalus Life Sciences stock worth more than $619,731 as of June 22nd. This net worth evaluation does not reflect any other assets that Wahlstrom may own. Learn More about Mats Wahlstrom's net worth.
How do I contact Mats Wahlstrom?
Has Mats Wahlstrom been buying or selling shares of TriSalus Life Sciences?
Over the course of the past ninety days, Mats Wahlstrom has bought $151,800.00 in TriSalus Life Sciences stock. Most recently, on Friday, May 15th, Mats Wahlstrom bought 60,000 shares of TriSalus Life Sciences stock. The stock was acquired at an average cost of $2.53 per share, with a total value of $151,800.00. Following the completion of the transaction, the director now directly owns 147,555 shares of the company's stock, valued at $373,314.15. Learn More on Mats Wahlstrom's trading history.
Who are TriSalus Life Sciences' active insiders?
Are insiders buying or selling shares of TriSalus Life Sciences?
During the last twelve months, TriSalus Life Sciences insiders bought shares 5 times. They purchased a total of 719,682 shares worth more than $1,804,176.38. During the last twelve months, insiders at the sold shares 11 times. They sold a total of 30,150 shares worth more than $119,849.35. The most recent insider tranaction occured on May, 15th when Director Mats Wahlstrom bought 60,000 shares worth more than $151,800.00. Insiders at TriSalus Life Sciences own 16.3% of the company.
Learn More about insider trades at TriSalus Life Sciences. Information on this page was last updated on 5/15/2026.
